Neoadjuvant checkpoint blockade for cancer immunotherapy
BACKGROUND Immunotherapies that target the interaction of programmed death 1 (PD-1)
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …
Revisiting neoadjuvant therapy in non-small-cell lung cancer
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial)
M Provencio, R Serna-Blasco, E Nadal… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Background Approximately 25% of all patients with non-small-cell lung cancer present with
resectable stage IB–IIIA disease, and although perioperative chemotherapy is the standard …
resectable stage IB–IIIA disease, and although perioperative chemotherapy is the standard …
[HTML][HTML] IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy
Currently, there is no established guidance on how to process and evaluate resected lung
cancer specimens after neoadjuvant therapy in the setting of clinical trials and clinical …
cancer specimens after neoadjuvant therapy in the setting of clinical trials and clinical …
Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee
M Mino-Kenudson, K Schalper, W Cooper… - Journal of Thoracic …, 2022 - Elsevier
Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A …
WZ Zhong, KN Chen, C Chen, CD Gu… - Journal of clinical …, 2019 - ascopubs.org
PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …
[HTML][HTML] Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches
Lung cancer is the leading cause of cancer-related deaths worldwide. Patients with
resectable NSCLC are often treated with surgery and adjuvant chemotherapy. However …
resectable NSCLC are often treated with surgery and adjuvant chemotherapy. However …
Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy
The treatment scenario for patients with resectable non–small cell lung cancer has changed
dramatically with the incorporation of immunotherapy. The introduction of immunotherapy …
dramatically with the incorporation of immunotherapy. The introduction of immunotherapy …
Pan-tumor pathologic scoring of response to PD-(L) 1 blockade
Purpose: Pathologic response assessment of tumor specimens from patients receiving
systemic treatment provides an early indication of therapeutic efficacy and predicts long-term …
systemic treatment provides an early indication of therapeutic efficacy and predicts long-term …